Share on StockTwits

Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) were the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 42,213,990 shares, a growth of 6.4% from the March 31st total of 39,661,474 shares, AnalystRatings.NET reports. Based on an average daily trading volume, of 12,728,856 shares, the short-interest ratio is presently 3.3 days. Approximately 23.4% of the shares of the stock are sold short.

ARIA has been the subject of a number of recent research reports. Analysts at BMO Capital Markets reiterated a “positive” rating on shares of Ariad Pharmaceuticals in a research note on Wednesday, March 26th. Separately, analysts at HC Wainwright initiated coverage on shares of Ariad Pharmaceuticals in a research note on Tuesday, March 25th. They set a “buy” rating and a $14.00 price target on the stock. Finally, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Ariad Pharmaceuticals in a research note on Thursday, February 27th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the company’s stock. Ariad Pharmaceuticals has a consensus rating of “Hold” and an average target price of $7.29.

Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 7.27 on Thursday. Ariad Pharmaceuticals has a 1-year low of $2.15 and a 1-year high of $23.00. The stock’s 50-day moving average is $7.59 and its 200-day moving average is $6.20. The company’s market cap is $1.355 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.47) by $0.07. The company had revenue of $8.28 million for the quarter, compared to the consensus estimate of $6.31 million. On average, analysts predict that Ariad Pharmaceuticals will post $-1.11 earnings per share for the current fiscal year.

ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.